1. Scrip
  2. >>R&D

Quick Acting Antibiotic Lends Promise To Destiny's Future

 
• By Sukaina Virji

Destiny Pharma's US NIAID-funded clinical study yields positive results for the novel quick-acting antibacterial exeporfinium chloride.

Destiny Pharma of the UK is developing XF-73 (exeporfinium chloride), an antibiotic for the prevention of post-surgical Staphylococcal infection, a new indication. The FDA granted the product Qualified Infectious Disease Product (QIDP) status last November. Earlier this year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, sponsored and funded a Phase I/IIa trial to study Staphylococcus aureus decolonization (i.e. the clearance of the bacteria from the nostrils of carriers). (Also see "'Rapid Kill' Antibiotic Awaits US Data For Blanket Decolonization Prior To Surgery " - Scrip, 3 March, 2016.)

In the US trial, XF-73 was shown to be safe and demonstrated a significant anti-staphylococcal effect after just 1 day...

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

More from Scrip

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.